Ezetimibe/Simvastatin

Tier C — Watch / trade

Merck & Co Inc

Originator

2004

First approval

Expiry (public)

No sales data

Peak sales

Small molecule

Type

Targets：HMGCR, NPC1L1

Brand：Vytorin, Inegy

Indications (approved)：Hyperlipoproteinaemia type II, Hyperlipidaemia, Coronary artery disease, 家族性混合型高脂血症

Regional status

Approved

2004-07-23

China

Approved

2009-04-15

Japan

Factories producing this API9

Factories registered as producing this API in our sourcing network (RFQ records + product master), sorted by RFQ activity; the snapshot carries no cost or customer data.

9 producing factories on file — sign in to view the named list (factory details are not shown to guests).

Synthetic routes & intermediates

Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.

Frequently asked questions

What are the approved indications of Ezetimibe/Simvastatin?

Approved indications include: Hyperlipoproteinaemia type II, Hyperlipidaemia, Coronary artery disease, 家族性混合型高脂血症.

When does the Ezetimibe/Simvastatin patent expire?

No public expiry year is available for Ezetimibe/Simvastatin yet; this page updates once verified.

How do I get a quote for Ezetimibe/Simvastatin intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-27